Cabaletta Bio, Inc. (CABA): Total Liabilities
$53.03M
As of 2025-12-31
$46.13M
As of 2026-06-30
+62.1%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.03M | +62.1% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $32.71M | +87.4% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $17.45M | +40.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $12.45M | +48.5% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $8.38M | n/a | 2023-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $53.03M | +62.1% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $32.52M | +6.5% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $21.32M | +17.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $8.30M | +122.3% |
| Tenaya Therapeutics, Inc. (TNYA) | 2025-12-31 | $23.66M | -12.7% |
Compare CABA, AURA, SABS, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗